ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug YL201 takes on tough esophageal cancer
Disease control Not yet recruitingThis large Phase 3 trial tests a new drug called YL201 against standard chemotherapy in 440 people with advanced esophageal cancer that has worsened after initial treatment. YL201 is a targeted therapy designed to deliver chemo directly to cancer cells. The study aims to see if i…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Smart MRI tailors cancer therapy for better outcomes
Disease control Not yet recruitingThis study tests a personalized approach for people with advanced esophageal cancer that cannot be removed by surgery. Doctors will use MRI scans to guide a custom combination of chemotherapy, radiation, and immunotherapy. The goal is to see if this tailored treatment can help ke…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for tough esophageal cancer: drug combo targets gene mutations
Disease control Not yet recruitingThis study tests whether a new combination of drugs (anlotinib hydrochloride plus benmelstobart) works better than the current standard treatment (toripalimab plus chemotherapy) for people with advanced esophageal cancer that has certain gene mutations. The trial will include 578…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a tiny dose of radiation reboot cancer immunotherapy?
Disease control Not yet recruitingThis phase II trial tests whether a single low dose of radiation to all visible tumors can help immunotherapy work again in people with advanced esophageal cancer that has stopped responding to standard treatment. Thirty-two adults will receive the radiation and continue their or…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 26, 2026 16:43 UTC